Tal Zaks

Tal Zaks, a physician-scientist and biotech executive who played a key role at Moderna during the COVID-19 vaccine development, shares his insights into turning scientific innovations into effective medicines. He discusses the challenges and opportunities in drug development, particularly in personalized therapies. Katie Ellenberg from Geneva Capital Management adds her perspective on investing in biotechnology, emphasizing the need for agility and collaboration in the sector. They also explore the transformative potential of AI and mRNA technology in healthcare.

Dr. Tal Zaks, CEO of Exsilio Therapeutics and former CMO at Moderna, shares insights on navigating the biotech landscape, including his transition from the COVID-19 crisis to launching his mRNA startup. He discusses the integration of cutting-edge gene therapy technologies and the challenges of moving from academic concepts to therapeutic applications. Zaks emphasizes the importance of public education on mRNA safety, the dual role of medicine in healing and wellness, and the future potential of AI in biotech innovation.

Tal Zaks, Chief Medical Officer at Moderna, discusses groundbreaking mRNA vaccine technology. Peggy Hamburg, former FDA commissioner, highlights the ethical and public health challenges in vaccine distribution. Andrew Lowe, a financial economist, offers insights into innovative funding models for medical research. They explore the rapid advancements in vaccine development during COVID-19, the importance of global equity in access, and the long-term implications for healthcare and pandemic preparedness.